Ivermectin Cream or Facial Eczema? What Rosacea Trials Show
Evidence review, updated November 2026. Ivermectin 1% cream is a prescription treatment for inflammatory lesions of rosacea. It is not an eczema cream. When facial redness, bumps, burning or dryness change after using it, the possibilities include rosacea activity, local irritation, contact dermatitis or another condition. The evidence below helps separate what the medicine was actually tested for from what it was not.
What the pivotal rosacea trials measured
Two identically designed 12-week randomized, double-blind trials compared once-daily ivermectin 1% cream with its vehicle in adults with moderate-to-severe papulopustular rosacea. “Clear” or “almost clear” was reached by 38.4% and 40.1% of the ivermectin groups, compared with 11.6% and 18.8% of vehicle groups. Inflammatory-lesion reductions were 76.0% and 75.0% with ivermectin versus 50.0% in each vehicle group.
A separate 16-week, investigator-blinded randomized trial enrolled 962 adults and compared ivermectin 1% once daily with metronidazole 0.75% twice daily. Mean inflammatory-lesion reduction was 83.0% versus 73.7%, and “clear” or “almost clear” proportions were 84.9% versus 75.4%. These results concern papulopustular rosacea, a specific diagnosis and outcome set. They do not establish efficacy for atopic dermatitis or any undiagnosed facial eruption.
| Evidence | Comparator | Reported result | Key boundary |
|---|---|---|---|
| Two 12-week trials | Vehicle cream | 38.4%/40.1% vs 11.6%/18.8% clear or almost clear | Rosacea, not eczema |
| 16-week trial; 962 adults | Metronidazole 0.75% cream | 83.0% vs 73.7% lesion reduction | Investigator-blinded; different dosing schedules |
| Official label | Clinical-trial safety data | Burning and irritation each at 1% or less | Trial rates may not predict one person’s reaction |
Can ivermectin cream itself irritate skin?
Yes, although the official U.S. label reports skin burning sensation and skin irritation among the most common adverse reactions at incidences of 1% or less in controlled trials. A low trial percentage does not mean a reaction is impossible, and it does not tell whether a new rash is irritant, allergic or unrelated. Trial populations and reporting rules also differ from everyday use.
Rosacea, eczema and contact dermatitis can overlap
Rosacea commonly favors the central face and can include persistent redness, flushing and inflammatory papules. Eczema often emphasizes itch, dryness and scaling, while allergic contact dermatitis may follow exposure patterns. These are tendencies, not a home diagnostic test. A clinician may need the exact distribution, medication timeline and sometimes patch testing or other evaluation.
Read our broader facial eczema-versus-rosacea guide, the evidence on metronidazole dryness and irritation, and the analysis of azelaic-acid irritation versus facial eczema.
Where #003 fits
Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat rosacea, eczema or medication reactions. The ivermectin results above belong to the tested prescription creams and cannot be transferred to #003.
Image disclosure: The image is an AI-created editorial illustration of a fictional adult with nonspecific facial redness. He is not a patient; the image does not show rosacea, eczema, a before/after result or a #003 outcome.
Continue the facial-treatment series
- Prescription tretinoin irritation versus facial eczema
- Brimonidine gel, flushing and dermatitis signals
Sources
- Two randomized vehicle-controlled ivermectin 1% rosacea trials (PubMed)
- Randomized ivermectin-versus-metronidazole rosacea trial (PubMed)
- Official DailyMed label for ivermectin cream
Educational information only. Persistent or worsening facial symptoms and prescription decisions belong with a qualified clinician.